With chronic diseases being the leading cause of death in the world, it comes as no surprise that management of these long-termdiseases is a top priority for healthcare systems around the world. For pharma and biotech involved in this area, there are manylucrative opportunities if the challenges caused by fierce competition for limited reimbursement funds and increasingly stringentregulations can be met.Chronic diseases are the largest cause of deaths in the world. The leading chronic diseases – cardiovascular disease, cancer, chronicrespiratory disease, and diabetes - cause 29 million deaths worldwide every year. It is 63% of total deaths worldwide and 86% ofdeaths across the 53 Member States in the WHO European Region. Therefore, it is the topic that should definitely be discussed.Health spending on chronic diseases is a long-term problem for payers who must prioritise their budgets in a difficult economicenvironment. Unfortunately, the number of diagnosed chronic diseases is increasing and pharmaceutical manufacturers have agreat opportunity to expand into this growing market; however access may be limited by budget restrictions, disease managementplans and other payer priorities. Chronic diseases are among one of the most important challenges facing health care systems.This web based forum will bring together senior industry experts, who will be discussing current challenges as well as future trendson how to stay competitive while improving patients’ quality of life.